|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,429.20 INR | -0.73% |
|
-0.98% | +39.07% |
| Sep. 10 | Indian Equities Extend Gains on Tuesday, Helped by IT, Pharma Stocks | MT |
| Aug. 28 | IT, Pharmaceutical Stocks Push Indian Equities to End Higher on Wednesday | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 1,452B 17.37B | P/E ratio 2025 * |
70.4x | P/E ratio 2026 * | 55.7x |
|---|---|---|---|---|---|
| Enterprise value | 875B 10.47B | EV / Sales 2025 * |
15.5x | EV / Sales 2026 * | 13.3x |
| Free-Float |
47.79% | Yield 2025 * |
0.54% | Yield 2026 * | 0.59% |
More valuation ratios
* Estimated data
More news
Last Transcript: Divi's Laboratories Limited
More recommendations
More press releases
| 1 day | +0.45% | ||
| 1 week | +0.20% | ||
| Current month | +7.85% | ||
| 1 month | +17.65% | ||
| 3 months | +22.64% | ||
| 6 months | +59.38% | ||
| Current year | +40.73% |
1 week
5 392.05
5 560.00
1 month
4 663.305 560.00
Current year
3 350.005 560.00
1 year
3 295.305 560.00
3 years
2 730.005 560.00
5 years
1 575.105 560.00
10 years
532.655 560.00
| Director | Title | Age | Since |
|---|---|---|---|
| Founder | 73 | 90-10-11 | |
| Chief Executive Officer | 46 | 01-08-09 | |
| Director of Finance/CFO | 74 | 94-11-19 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 01-08-09 | |
| Founder | 73 | 90-10-11 | |
| Director/Board Member | 66 | 94-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.68% | 6 M€ | +6.07% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.51% | +0.20% | +45.36% | +7.51% | 17.35B | ||
| -0.13% | -1.73% | +58.41% | +293.29% | 816B | ||
| +1.90% | -0.93% | +35.64% | +174.23% | 583B | ||
| -0.55% | +0.81% | +2.27% | +0.85% | 402B | ||
| -0.26% | -0.85% | +25.33% | +79.10% | 342B | ||
| +0.30% | +3.43% | +10.04% | +65.51% | 300B | ||
| +0.71% | -0.15% | +4.05% | -21.73% | 255B | ||
| +0.79% | -3.67% | +10.51% | +47.04% | 243B | ||
| +0.46% | +0.58% | +6.54% | +26.60% | 235B | ||
| +0.04% | +0.89% | +26.51% | +51.75% | 179B | ||
| Average | +0.55% | -0.21% | +22.47% | +72.42% | 337.15B | |
| Weighted average by Cap. | +0.58% | -0.57% | +27.19% | +121.43% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 90.98B 1.09B | 106B 1.27B |
| Net income | 20.59B 246M | 26.02B 311M |
| Net Debt | -38.75B -464M | -41.77B -500M |
More financial data
* Estimated data
Employees
9,741
Sector
Pharmaceuticals
Calendar
2024-11-03
- Q2 2025 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-19 | 5,429.20 ₹ | -0.73% | 341,889 |
| 24-09-18 | 5,469.15 ₹ | +0.31% | 213,575 |
| 24-09-17 | 5,452.20 ₹ | -0.50% | 529,121 |
| 24-09-16 | 5,479.35 ₹ | -0.35% | 238,494 |
| 24-09-13 | 5,498.65 ₹ | +0.29% | 401,361 |
Delayed Quote NSE India S.E., September 19, 2024 at 02:48 am EDT
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
5,469.15INR
Average target price
4,457.08INR
Spread / Average Target
-18.51%
- Stock Market
- Equities
- DIVISLAB Stock